R&D News | pharmaphorum

News

UK “keeping up momentum” on clinical trials review

Lord James O’Shaughnessy has welcomed the UK government’s official response to his review of commercial clinical trials, saying there have been a number of positive develo

News

InDex craters on phase 3 ulcerative colitis failure

InDex Pharmaceuticals has said it will abandon a phase 3 trial of its lead drug cobitolimod in moderate-to-severe ulcerative colitis, its only clinical-stage programme, wr

News

Moderna completes next stage of UK R&D facility build

US biotech Moderna has completed the installation of its clinical laboratories at its new R&D facility in the UK dedicated to the discovery of new mRNA vaccines and th

News

UK's Autumn Budget welcomed by pharma trade organisations

The life sciences industry in the UK has responded positively to measures introduced in the Autumn Budget detailed today by Chancellor Jeremy Hunt, including confirmation

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

Genentech, NVIDIA partner on ‘lab-in-a-loop’ AI platform

NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s Genentech subsidiary aimed at accelerating the use of generative artifici

UK “keeping up momentum” on clinical trials review

InDex craters on phase 3 ulcerative colitis failure

Moderna completes next stage of UK R&D facility build

UK's Autumn Budget welcomed by pharma trade organisations

Boehringer buys cancer immunotherapy firm T3 for $507m

Genentech, NVIDIA partner on ‘lab-in-a-loop’ AI platform

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks